A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Metastatic Castrate-Resistant Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase of Trial: Phase I
Latest Information Update: 27 Mar 2018
At a glance
- Drugs ABBV-744 (Primary)
- Indications Acute myeloid leukaemia; Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 20 Mar 2018 Planned End Date changed from 19 Mar 2020 to 20 Apr 2020.
- 20 Mar 2018 Status changed from not yet recruiting to recruiting.
- 06 Mar 2018 Planned End Date changed from 29 Feb 2020 to 19 Mar 2020.